Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orion Diagnostica's new Collagen Intact Pinp radioimmunoassay's (RIA) for type I collagen:

This article was originally published in Clinica

Executive Summary

Orion Diagnostica (Finland) has released its new Collagen Intact PINP radioimmunoassay (RIA) for in vitro quantitative measurement of intact type I procollagen N-terminal propeptide in human serum. The assay, indicated for use in monitoring type I collagen formation, is not affected by small molecular weight degradation products of the propeptide, the company claims. The company has also released its new Collagen Rat-ICTP RIA, developed for in vitro measurement of type I collagen C-terminal cross-linked telopeptide in rat samples. The RIA is designed for use in the preclinical monitoring of therapies targeting bone-degrading diseases.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel